Abstract
Programmable RNA pseudouridylation has emerged as a new type of RNA base editor to suppress premature termination codons (PTCs) that can lead to truncated and nonfunctional proteins. However, current methods to correct disease-associated PTCs suffer from low efficiency and limited precision. Here we develop RESTART v3, which uses near-cognate tRNAs to improve the readthrough efficiency of pseudouridine-modified PTCs. We show an average of ~5-fold (range: 2.1- to 9.5-fold) higher editing efficiency than RESTART v2 in cultured cells and achieve functional PTC readthrough in disease cell models of cystic fibrosis and Hurler syndrome. Furthermore, RESTART v3 enables accurate incorporation of the original amino acid for nearly half of the PTC sites, considering the naturally occurring frequencies of sense-to-nonsense codons, without affecting normal termination codons. Although off-target sites were detected, we did not observe changes to the coding information or the expression level of transcripts, and the overall natural tRNA abundance remained constant.
This is a preview of subscription content, access via your institution
Access options
Access Nature and 54 other Nature Portfolio journals
Get Nature+, our best-value online-access subscription
$29.99 / 30 days
cancel any time
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
Data availability
The sequence data generated in this study have been deposited in the NCBI Gene Expression Omnibus (GEO), under accession code GSE237633 (ref. 57). Source data are provided with this paper.
References
Krawczak, M., Ball, E. V. & Cooper, D. N. Neighboring-nucleotide effects on the rates of germ-line single-base-pair substitution in human genes. Am. J. Hum. Genet. 63, 474–488 (1998).
Mort, M., Ivanov, D., Cooper, D. N. & Chuzhanova, N. A. A meta-analysis of nonsense mutations causing human genetic disease. Hum. Mutat. 29, 1037–1047 (2008).
Cheng, S. H. et al. Defective intracellular transport and processing of CFTR is the molecular basis of most cystic fibrosis. Cell 63, 827–834 (1990).
Ballabio, A. & Gieselmann, V. Lysosomal disorders: from storage to cellular damage. Biochim. Biophys. Acta. 1793, 684–696 (2009).
Howard, M., Frizzell, R. A. & Bedwell, D. M. Aminoglycoside antibiotics restore CFTR function by overcoming premature stop mutations. Nat. Med. 2, 467–469 (1996).
Welch, E. M. et al. PTC124 targets genetic disorders caused by nonsense mutations. Nature 447, 87–91 (2007).
Dabrowski, M., Bukowy-Bieryllo, Z. & Zietkiewicz, E. Advances in therapeutic use of a drug-stimulated translational readthrough of premature termination codons. Mol. Med. 24, 25 (2018).
Lueck, J. D. et al. Engineered transfer RNAs for suppression of premature termination codons. Nat. Commun. 10, 822 (2019).
Wang, J. et al. AAV-delivered suppressor tRNA overcomes a nonsense mutation in mice. Nature 604, 343–348 (2022).
Albers, S. et al. Engineered tRNAs suppress nonsense mutations in cells and in vivo. Nature 618, 842–848 (2023).
Temple, G. F., Dozy, A. M., Roy, K. L. & Kan, Y. W. Construction of a functional human suppressor tRNA gene: an approach to gene therapy for β-thalassaemia. Nature 296, 537–540 (1982).
Kiselev, A. V. et al. Suppression of nonsense mutations in the Dystrophin gene by a suppressor tRNA gene. Mol. Biol. (Mosk). 36, 43–47 (2002).
Cox, D. B. T. et al. RNA editing with CRISPR–Cas13. Science 358, 1019–1027 (2017).
Merkle, T. et al. Precise RNA editing by recruiting endogenous ADARs with antisense oligonucleotides. Nat. Biotechnol. 37, 133–138 (2019).
Qu, L. et al. Programmable RNA editing by recruiting endogenous ADAR using engineered RNAs. Nat. Biotechnol. 37, 1059–1069 (2019).
Katrekar, D. et al. In vivo RNA editing of point mutations via RNA-guided adenosine deaminases. Nat. Methods 16, 239–242 (2019).
Vogel, P. et al. Efficient and precise editing of endogenous transcripts with SNAP-tagged ADARs. Nat. Methods 15, 535–538 (2018).
Huang, X. et al. Programmable C-to-U RNA editing using the human APOBEC3A deaminase. EMBO J. 39, e104741 (2020).
Abudayyeh, O. O. et al. A cytosine deaminase for programmable single-base RNA editing. Science 365, 382–386 (2019).
Rauch, S. et al. Programmable RNA-guided RNA effector proteins built from human parts. Cell 178, 122–134 (2019).
Reautschnig, P. et al. CLUSTER guide RNAs enable precise and efficient RNA editing with endogenous ADAR enzymes in vivo. Nat. Biotechnol. 40, 759–768 (2022).
Yi, Z. et al. Engineered circular ADAR-recruiting RNAs increase the efficiency and fidelity of RNA editing in vitro and in vivo. Nat. Biotechnol. 40, 946–955 (2022).
Katrekar, D. et al. Efficient in vitro and in vivo RNA editing via recruitment of endogenous ADARs using circular guide RNAs. Nat. Biotechnol. 40, 938–945 (2022).
Xu, C. et al. Programmable RNA editing with compact CRISPR–Cas13 systems from uncultivated microbes. Nat. Methods 18, 499–506 (2021).
Kannan, S. et al. Compact RNA editors with small Cas13 proteins. Nat. Biotechnol. 40, 194–197 (2022).
Song, J. et al. CRISPR-free, programmable RNA pseudouridylation to suppress premature termination codons. Mol. Cell 83, 139–155 (2023).
Adachi, H. et al. Targeted pseudouridylation: an approach for suppressing nonsense mutations in disease genes. Mol. Cell 83, 637–651 (2023).
Montes, M. & Martinez, N. M. Rewriting the message: harnessing RNA pseudouridylation to tackle disease. Mol. Cell 83, 503–506 (2023).
Karijolich, J. & Yu, Y. T. Converting nonsense codons into sense codons by targeted pseudouridylation. Nature 474, 395–398 (2011).
Lowe, T. M. & Eddy, S. R. tRNAscan-SE: a program for improved detection of transfer RNA genes in genomic sequence. Nucleic Acids Res. 25, 955–964 (1997).
Geslain, R. & Pan, T. Functional analysis of human tRNA isodecoders. J. Mol. Biol. 396, 821–831 (2010).
Zhang, M. et al. Quantitative profiling of pseudouridylation landscape in the human transcriptome. Nat. Chem. Biol. 19, 1185–1195 (2023).
Kotha, K. & Clancy, J. P. Ivacaftor treatment of cystic fibrosis patients with the G551D mutation: a review of the evidence. Ther. Adv. Respir. Dis. 7, 288–296 (2013).
Kerem, E. Pharmacologic therapy for stop mutations: how much CFTR activity is enough? Curr. Opin. Pulm. Med. 10, 547–552 (2004).
Bunge, S. et al. Genotype-phenotype correlations in mucopolysaccharidosis type I using enzyme kinetics, immunoquantification and in vitro turnover studies. Biochim. Biophys. Acta 1407, 249–256 (1998).
Oussoren, E. et al. Residual α-L-iduronidase activity in fibroblasts of mild to severe Mucopolysaccharidosis type I patients. Mol. Genet. Metab. 109, 377–381 (2013).
Sun, H., Li, K., Liu, C. & Yi, C. Regulation and functions of non-m(6)A mRNA modifications. Nat. Rev. Mol. Cell Biol. 24, 714–731 (2023).
Kierzek, E. et al. The contribution of pseudouridine to stabilities and structure of RNAs. Nucleic Acids Res. 42, 3492–3501 (2014).
Keeling, K. M., Xue, X., Gunn, G. & Bedwell, D. M. Therapeutics based on stop codon readthrough. Annu. Rev. Genomics Hum. Genet. 15, 371–394 (2014).
McClain, W. H., Foss, K., Jenkins, R. A. & Schneider, J. Nucleotides that determine Escherichia coli tRNA(Arg) and tRNA(Lys) acceptor identities revealed by analyses of mutant opal and amber suppressor tRNAs. Proc. Natl Acad. Sci. USA 87, 9260–9264 (1990).
Giege, R. & Eriani, G. The tRNA identity landscape for aminoacylation and beyond. Nucleic Acids Res. 51, 1528–1570 (2023).
Pechmann, S. & Frydman, J. Evolutionary conservation of codon optimality reveals hidden signatures of cotranslational folding. Nat. Struct. Mol. Biol. 20, 237–243 (2013).
Porter, J. J., Heil, C. S. & Lueck, J. D. Therapeutic promise of engineered nonsense suppressor tRNAs. Wiley Interdiscip. Rev. RNA 12, e1641 (2021).
Eyler, D. E. et al. Pseudouridinylation of mRNA coding sequences alters translation. Proc. Natl Acad. Sci. USA 116, 23068–23074 (2019).
Prakash, T. P. et al. Targeted delivery of antisense oligonucleotides to hepatocytes using triantennary N-acetyl galactosamine improves potency 10-fold in mice. Nucleic Acids Res. 42, 8796–8807 (2014).
Zheng, G. et al. Efficient and quantitative high-throughput tRNA sequencing. Nat. Methods 12, 835–837 (2015).
Li, X. et al. Transcriptome-wide mapping reveals reversible and dynamic N(1)-methyladenosine methylome. Nat. Chem. Biol. 12, 311–316 (2016).
Lu, B. et al. Transposase-assisted tagmentation of RNA/DNA hybrid duplexes. eLife 9, e54919 (2020).
Dobin, A. et al. STAR: ultrafast universal RNA-seq aligner. Bioinformatics 29, 15–21 (2013).
Danecek, P. et al. Twelve years of SAMtools and BCFtools. GigaScience 10, giab008 (2021).
Putri, G. H., Anders, S., Pyl, P. T., Pimanda, J. E. & Zanini, F. Analysing high-throughput sequencing data in Python with HTSeq 2.0. Bioinformatics 38, 2943–2945 (2022).
Eisenberg, E. & Levanon, E. Y. Human housekeeping genes, revisited. Trends Genet. 29, 569–574 (2013).
Hounkpe, B. W., Chenou, F., de Lima, F. & De Paula, E. V. HRT Atlas v1.0 database: redefining human and mouse housekeeping genes and candidate reference transcripts by mining massive RNA-seq datasets. Nucleic Acids Res. 49, D947–D955 (2021).
Smith, T., Heger, A. & Sudbery, I. UMI-tools: modeling sequencing errors in unique molecular identifiers to improve quantification accuracy. Genome Res. 27, 491–499 (2017).
Li, H. & Durbin, R. Fast and accurate short read alignment with Burrows–Wheeler transform. Bioinformatics 25, 1754–1760 (2009).
Shen, W., Le, S., Li, Y. & Hu, F. SeqKit: a cross-platform and ultrafast toolkit for FASTA/Q file manipulation. PLoS ONE 11, e0163962 (2016).
Luo, N. et al. Near-cognate tRNAs increase the efficiency and precision of pseudouridine-mediated readthrough of premature termination codons. GEO. www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE237633 (2024).
Acknowledgements
The authors would like to thank the National Center for Protein Sciences at Peking University in Beijing, China, for assistance with the 4150 TapeStation System, Cell Imaging Multimode Reader (BioTek Cytation 5) and mass spectrometry; D. Liu and Q. Zhang for their help with mass spectrometry sample pretreatment and data analysis; the Center for Quantitative Biology at Peking University for assistance with the ImageXpress Micro 4 high-content imaging system and X. Li for her help; High Performance Computing Platform of the Center for Life Science (Peking University) for assistance with the analysis; and the Large-Scale Instrument Platform of State Key Laboratory of Natural and Biomimetic Drugs at Peking University for its advance and support in technology; Cystic Fibrosis Foundation for providing 16HBEge cells; and M. Zhang and Y. Ma for their discussion. This work was supported by the Ministry of Agriculture and Rural Affairs of China (NK2022010102 to C.Y.), the Natural Science Foundation of China (21825701 to C.Y. and 32200467 to Q.H.), the Ministry of Science and Technology of China (2023YFC3402200 to C.Y.), the Beijing Municipal Science and Technology Commission (Z231100002723005 to C.Y.) and the China Postdoctoral Science Foundation (2022M710222 to Q.H.).
Author information
Authors and Affiliations
Contributions
C.Y. and N.L. conceived the project and designed the experiments. N.L., L.D. and Q.H. performed the experiments with the help of J.S., H.S. and Y.G. N.L. and L.D. designed and conducted all sample preparation for NGS. W.L. performed the bioinformatic analysis with the help of H.W. C.Y. supervised the project. C.Y., N.L., L.D. and Q.H. wrote the manuscript with contributions from all authors.
Corresponding author
Ethics declarations
Competing interests
A patent has been filed relating to the data presented.
Peer review
Peer review information
Nature Biotechnology thanks the anonymous reviewers for their contribution to the peer review of this work.
Additional information
Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Supplementary information
Supplementary Information
Supplementary Figs. 1–6.
Supplementary Tables
Supplementary Table 1: Sequence of tRNA and primer. Supplementary Table 2: The composition of each version of the RESTART system (a) and the near-cognate tRNAs used in RESTART v3 and v3-mini (b). Supplementary Table 3: Primer information. Supplementary Table 4: Survey of human pathogenic nonsense mutations. Supplementary Table 5: list of detected off-target sites. Supplementary Table 6: Identification of the corresponding amino acid(s) incorporated at the off-target pseudouridine sites.
Supplementary Data 1
Statistical supporting data of Supplementary Figs. 1–6.
Source data
Source Data Figs. 1–5.
Statistical source data.
Rights and permissions
Springer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law.
About this article
Cite this article
Luo, N., Huang, Q., Dong, L. et al. Near-cognate tRNAs increase the efficiency and precision of pseudouridine-mediated readthrough of premature termination codons. Nat Biotechnol (2024). https://doi.org/10.1038/s41587-024-02165-8
Received:
Accepted:
Published:
DOI: https://doi.org/10.1038/s41587-024-02165-8